ClinicalTrials.gg
Not yet recruitingNCT07785921HerzAktivUpdated Aug 31, 2026

Health Behaviour and Readiness to Change After Myocardial Infarction: A Cross-sectional Survey

An observational study in Cardiovascular (CV) Risk and Heart Attack Patients, sponsored by Kliniken Essen-Mitte. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Kliniken Essen-Mitte · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
143
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 159 studies in Myocardial Infarction with a site in Germany — 13 open to participants now, 17 under way, 5 of them phase 3. Myocardial Infarction · Germany.

Planned enrollment
41st of 51
143 · median 750
Started
2026
with 2 others
Observational
52 of 159
5 open now
Primary completion
2027-03
later than 5 of 16 live
Registered
159th of 159
by date

Among the 159 studies in Myocardial Infarction with a site in Germany, this one is the 41st largest by planned enrollment of the 51 observational ones that give a count, is one of 3 that started in 2026, is one of 52 observational ones, reaches primary completion later than 5 of the 16 other live ones, and was the 159th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

13 of the 159 studies in Myocardial Infarction with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 159 studies in Myocardial Infarction with a site in Germany, or all of them as a file.
02

Study summary

This study investigates health behaviour and readiness for lifestyle change in patients who recently had a heart attack (myocardical infarction) treated with stenting (PTCA). Despite successful acute treatment, many patients remain at increased risk of a second heart atttack because lifestyle changes are not consistently maintained. Participants who had a heart attack within the past 6 months will complete standardized questionnaires on readiness to change, quality of life, anxiety/depression, and physical functioning, plus a free-text section on personal barriers to change. Findings will characterize this population and inform a future lifestyle intervention trial

Read the detailed description

Cardiovascular diseses are the leading cause of deaths in Germany and worldwide. Even after successfull PTCA, reinfarction rates remain elevated, partly because patients often underestimate their ongoing risk, have limited knowledge of secondary prevention targets and show low self-efficacy for behavior change; anxiety and depression are also common after myocardial infarction.

This single-center, cross-sectional study enrolls patients treated with PTCA within the past 6 months, recruited during their routine follow-up visit at the Lipidambulanz, Westdeutsches Herz- und Gefäßzentrum, University Hospital Essen. Participants complete validated questionnaires: PIAC (primary outcome; rediness to change), SF-36 (quality of life); HADS (anxiety/depression), and KCCQ-23 (physical functioning), plus sociodemographic data and free-text section on perceived barriers.

This study is purely observational, involves no interventions or biospecimens and takes about 30 minutes. A sample of 143 participants was calculated for adequate precision in estimating the PIAC meand and supporting exploratory regression analyses, accounting for 10% dropout. Data collection runs 6 months, followed by 18 months of analysus. Results wull inform a planned randomized controlled trial.

03

Conditions studied

  • Cardiovascular (CV) Risk
  • Heart Attack Patients

Keywords

  • secondary prevention
  • prevention
  • heart attack
  • lifestyle modification
  • cardiovascular disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from the catchment area of the Westdeutsches Herz- und Gefäßzentrum, University Hospital Essen, treated for acute myocardial infarction with PTCA. Recruitment and eligibility screening take place during the routine post-discharge follow-up visit at the Lipidambulanz, within approx. 3 months. after the index event. creening is performed by the treating physician within the existing doctor-patient relationshop, without recording study-specifix personal data. Eligible patients are approached in person by a stdy physician and enrolled only after written informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age over 18 years
  • myocardial infarction within past 6 months
  • PTCA treatment

Exclusion criteria

Exclusion Criteria:

  • Age under 18
  • history of multiple myocardial infactionrs
  • myocardial infarction more than 6 months prior
  • myocardial infarction not treated by PTCA
  • absence of
  • severe cognitive impairment precluding data collection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
143 participants (estimated)
Patient registry
No

Groups and cohorts

  • Post-Myocardial Infarction Patients

    Patients aged 18 years or older who experienced a myocardical infarction within the past 6 months, treated with percutaneous transluminal coronary angioplasty (PTCA), and recruited during ther routine post-discharge follow-up visit at the Lipidambulanz (lipid outpatient clinic), Westdeutsches Herz- und Gefäßzentrum, University Hospital Essen. Participants complete a one-time set of questionnaires.

06

What researchers measure

Primary outcomes

  1. PIAC (Perception, Intention and Ability to Change) Scale

    Readiness and ability to change health-related behavior, habits and living conditions, assessed using the PIAC questionnaire, a validated 9 item instrument covering awareness of negative health behaviors, intention to change and implementation of change strategies. Higher scores indicate a better awareness and intention to change.

    Time frame: Single assessement at study enrollment, baseline

Secondary outcomes

  1. SF-36 (Short-form 36 Health Survey)

    Health-related quality of life assessed using the SF-36, yielding a physical and a mental summary score; higher scores indicate better quality of life.

    Time frame: Single assessement at study enrollment, baseline

  2. HADS (Hospital Anxiety and Depression Scale)

    Anxiety and depressive Symptoms assessed using the HADS(-A) for Anxiety and HADS-(D) for depression. each ssubscales ranges from 0-21; higher scores indicate greater severity.

    Time frame: Single assessement at study enrollment, baseline

  3. KCCQ-23 (Kansas City Cardiomyopathy Questionnaire)

    Disease-specific health status using the KCCQ-23 covering physical limitations, symptoms, self-efficacy, social limitation and quality of life. Scores ranging 0-100 with higher scores indicating better health status.

    Time frame: Single assessement at study enrollment, baseline

07

Study locations

1 site
08

References and documents

Publications

  • Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000 Apr;35(5):1245-55. doi: 10.1016/s0735-1097(00)00531-3. PubMed 10758967 ↗
  • Endler NS, Hunt JM. Generalizability of contributions from sources of variance in the S-R inventories of anxiousness. J Pers. 1969 Mar;37(1):1-24. doi: 10.1111/j.1467-6494.1969.tb01728.x. No abstract available. PubMed 5778965 ↗
  • Chen JJ, Anand SK, Porter PJ. Infectious mononucleosis with thrombocytopenic purpura. Pediatrics. 1968 Feb;41(2):526-8. No abstract available. PubMed 5688970 ↗
  • Lehmann N, Paul A, Moebus S, Budde T, Dobos GJ, Michalsen A. Effects of lifestyle modification on coronary artery calcium progression and prognostic factors in coronary patients--3-year results of the randomized SAFE-LIFE trial. Atherosclerosis. 2011 Dec;219(2):630-6. doi: 10.1016/j.atherosclerosis.2011.08.050. Epub 2011 Sep 6. PubMed 21944697 ↗
  • Sanchez Angulo JI, Cuesta Lopez MJ, Zapata Lopez A, Perez Cortes S. [HIV infection and porphyria cutanea tarda]. Enferm Infecc Microbiol Clin. 1997 Aug-Sep;15(7):392-3. No abstract available. Spanish. PubMed 9410059 ↗
  • Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998 Dec 16;280(23):2001-7. doi: 10.1001/jama.280.23.2001. PubMed 9863851 ↗
  • Nguyen XT, Li Y, Wang DD, Whitbourne SB, Houghton SC, Hu FB, Willett WC, Sun YV, Djousse L, Gaziano JM, Cho K, Wilson PW; VA Million Veteran Program. Impact of 8 lifestyle factors on mortality and life expectancy among United States veterans: The Million Veteran Program. Am J Clin Nutr. 2024 Jan;119(1):127-135. doi: 10.1016/j.ajcnut.2023.10.032. Epub 2023 Dec 7. PubMed 38065710 ↗
  • Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937-52. doi: 10.1016/S0140-6736(04)17018-9. PubMed 15364185 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2026
First posted
Aug 25, 2026
StartEst.
Sep 15, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
Sep 30, 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07785921
Lead sponsor
Kliniken Essen-Mitte
Collaborators
Universitätsklinikum Essen
Responsible party
Kohl, Wiebke (Dr.med., Universitätsklinikum Essen) — Principal investigator
First posted
Aug 25, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

Wiebke K Kohl-Heckl, Dr.med.
Contact
w.kohl-heckl@kem-med.com
004920117425012
Wiebke Kohl, Dr.med
principal investigator · Center for Integrative Medicine and Planetary Health, University Hospital Essen
Gustav Dobos, Prof. Dr. med.
study director · Center for Integrative Medicine and Planetary Health, University Hospital Essen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion